Royalty Pharma PLC $RPRX Stock: Voya Investment Management LLC Boosts Position

Royalty Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management increased its Royalty Pharma stake by 104.7% in the third quarter, adding 302,662 shares to hold 591,714 shares valued at about $34.5 million. Institutional investors own 54.35% of the stock.
  • Analyst sentiment is broadly positive: the stock has a consensus “Buy” rating and a $65 average price target, while Citigroup and TD Cowen raised their targets to $78 and $80, respectively.
  • Company insiders sold 440,788 shares worth about $29.2 million over the past 90 days, under pre-arranged trading plans. Royalty Pharma also announced a quarterly dividend of $0.235 per share, equivalent to a 1.4% yield.
  • MarketBeat previews the top five stocks to own by December 1st.

Voya Investment Management LLC grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 104.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 591,714 shares of the biopharmaceutical company's stock after purchasing an additional 302,662 shares during the period. Voya Investment Management LLC owned approximately 0.10% of Royalty Pharma worth $34,532,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Provenance Wealth Advisors LLC purchased a new stake in Royalty Pharma in the 3rd quarter valued at about $26,000. CoreCap Advisors LLC boosted its stake in Royalty Pharma by 89.2% during the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 413 shares during the period. Bessemer Group Inc. boosted its stake in Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 282 shares during the period. Root Financial Partners LLC acquired a new stake in shares of Royalty Pharma during the third quarter valued at about $62,000. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in shares of Royalty Pharma during the third quarter valued at about $63,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RPRX has been the topic of a number of research analyst reports. Citigroup boosted their price target on shares of Royalty Pharma from $70.00 to $78.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Weiss Ratings raised shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. Wall Street Zen raised shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 14th. TD Cowen lifted their target price on shares of Royalty Pharma from $68.00 to $80.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Morgan Stanley boosted their target price on Royalty Pharma from $65.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $65.00.

Read Our Latest Stock Analysis on RPRX

Insider Activity

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the firm's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total transaction of $6,815,000.00. Following the transaction, the executive vice president owned 177,523 shares of the company's stock, valued at approximately $12,098,192.45. This trade represents a 36.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 232,536 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total transaction of $16,014,754.32. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 440,788 shares of company stock worth $29,157,162. 18.84% of the stock is currently owned by insiders.

Royalty Pharma Stock Down 1.4%

Shares of NASDAQ RPRX opened at $67.72 on Friday. The business's fifty day simple moving average is $62.11 and its 200-day simple moving average is $55.08. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. Royalty Pharma PLC has a 12-month low of $37.31 and a 12-month high of $70.37. The stock has a market cap of $38.84 billion, a P/E ratio of 56.43, a PEG ratio of 1.36 and a beta of 0.37.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma's payout ratio is 78.33%.

Royalty Pharma Profile

(Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Further Reading

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Royalty Pharma Right Now?

Before you consider Royalty Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.

While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines